Therapeutic Area: Oncology

Epcoritamab in relapsed/refractory large B-cell lymphoma:2-year follow-up from the pivotal EPCORE NHL-1 trial

Thieblemont C, et al.
Leukemia
September 2024
Authors and Affiliates
Catherine Thieblemont 1✉, Yasmin H. Karimi2, Herve Ghesquieres3, Chan Y. Cheah4, Michael Roost Clausen5, David Cunningham6, Wojciech Jurczak 7, Young Rok Do8, Robin Gasiorowski 9, David John Lewis10, Tae Min Kim 11, Marjolein van der Poel12, Michelle Limei Poon13, Tatyana Feldman14, Kim M. Linton15, Anna Sureda 16, Martin Hutchings17, Minh H. Dinh 18, Nurgul Kilavuz19, David Soong19, Thomas Mark20, Mariana Sacchi19, Tycel Phillips21,23 and Pieternella J. Lugtenburg22 1Assistance Publique & Hôpitaux de Paris (APHP), Hôpital Saint-Louis, Hémato-oncologie, Université de Paris, Paris, France. 2Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. 3Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre-Bénite, France. 4Sir Charles Gairdner Hospital and the University of Western Australia, Nedlands, Australia. 5Vejle Hospital, Vejle, Denmark. 6The Royal Marsden NHS Foundation Trust, Sutton, UK. 7MSC National Research Institute of Oncology, Kraków, Poland. 8Keimyung University Dongsan Medical Center, Daegu, Republic of Korea. 9Concord Hospital, University of Sydney, Sydney, Australia. 10University Hospitals Plymouth NHS Trust, Derriford Hospital, Plymouth, UK. 11Seoul National University Hospital, Seoul, Republic of Korea. 12Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Maastricht, Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands. 13National University Hospital, Singapore, Singapore. 14John Theurer Cancer Center at Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA. 15The Christie NHS Foundation Trust, Manchester Cancer Research Centre, and Division of Cancer Sciences, University of Manchester, Manchester, UK. 16Clinical Hematology Department, Institut Català d’Oncologia – L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain. 17Rigshospitalet and University of Copenhagen, Copenhagen, Denmark. 18AbbVie, North Chicago, IL, USA. 19Genmab, Plainsboro, NJ, USA. 20Genmab, Copenhagen, Denmark. 21University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. 22Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Erasmus MC Cancer Institute, Department of Hematology, University Medical Center, Rotterdam, The Netherlands. 23Present address: City of Hope, Duarte, CA, USA. ✉email: catherine.thieblemont@aphp.fr

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma(MOLTO): a multicentre, single-arm, phase 2 trial

Tedeschi A, et al.
Lancet Oncology
September 2024
Authors and Affiliates
Alessandra Tedeschi*, Anna Maria Frustaci*, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valentina Griggio, Georg Stüssi, Angelica Calleri, Katia Pini, Roberto Cairoli, Thorsten Zenz, Alessio Signori, Emanuele Zucca, Davide Rossi, Marco Montillo Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy (A Tedeschi MD, A M Frustaci MD, M Deodato MD, R Cairoli MD, M Montillo MD); Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland (A Condoluci MD, Prof D Rossi MD, K Pini BS, Prof E Zucca MD); Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland (A Condoluci, Prof D Rossi, Prof G Stüssi MD, Prof E Zucca MD); University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy (R Jones MD, V Griggio PhD); Department of Oncology ASST Sette Laghi,\ Ospedale di Circolo, Varese, Italy (Prof M Coscia MD);Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy (Prof R Chiarle MD, V Tabanelli MD, A Calleri PhD); Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy (Prof R Chiarle); Department of Pathology, Boston Children’s Hospital, Boston, MA, USA (Prof R Chiarle); Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “L e A Seràgnoli”, Bologna, Italy

Case report of fatal immune-mediatedmyocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependentCD28 costimulator and dualPD-L1/CTLA-4checkpoint inhibitor, incombination with pembrolizumab

Cavalcante L., et al.
Journal for ImmunoTherapy of Cancer
August 2024
Authors and Affiliates
Ludimila Cavalcante, Sreenivasa Chandana, Nehal Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar.

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia

Srinagesh H, et al.
Blood
July 2024
Authors and Affiliates
Hrishikesh Srinagesh1 , Clayton Jackson2 , Parveen Shiraz3 , Nikeshan Jeyakumar1 , Mark Hamilton1 , Emily Egeler4 , Sharon Mavroukakis4 , Adam Kuo4 , Juancarlos Cancilla4 , Bita Sahaf4 , Neha Agarwal3 , Alyssa Kanegai3 , Anne Marijn Kramer3,4 , Sally Arai3 , Sushma Bharadwaj3 , Saurabh Dahiya3 , Hitomi Hosoya3 , Laura Johnston3 , Vanessa Kennedy3 , Michaela Liedtke1 , Robert Lowsky3 , Lekha Mikkilineni3 , Robert Negrin3 , Andrew Rezvani3 , Surbhi Sidana3 , Judith Shizuru3 , Melody Smith3 , Wen-Kai Weng3 , Steven Feldman4 , Matthew J. Frank3,4 , Zachary Lee5 , Mary Tagliaferri5 , A. Mario Marcondes5 , David Miklos3,4 , Crystal Mackall4 , Lori Muffly3,4 Division of Hematology/Oncology, UT Southwestern, Dallas, TX; 3 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford CA; 4 Center for Cancer Cell Therapy, Stanford University, Stanford, CA; 5 Nektar Therapeutics, San Francisco, CA

Molecular disease monitoring in patients with relapsed/refractory B-cell lymphoma receiving anti-CD19 CAR T-cell therapy

Colton M, et al.
Clinical Lymphoma Myeloma & Leukemia
June 2024
Authors and Affiliates
Colton, Meryl MD MSc1; Purev, Enkhtsetseg MD1; Haverkos, Bradley MD MPH1; Bair, Steven MD1; Jasem, Jagar MD MPH1; Allison Jacob MS2; Kamdar, Manali MD1 1. Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO 2. Adaptive Biotechnologies, Seattle WA

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

Melani C, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
C. Melani, R. Lakhotia, S. Pittaluga, J.D. Phelan, D.W. Huang, G. Wright, J. Simard, J. Muppidi, C.J. Thomas, M. Ceribelli, F.A. Tosto, Y. Yang, W. Xu, T. Davies‑Hill, S.D. Pack, C.J. Peer, O. Arisa, E. Mena, L. Lindenberg, E. Bergvall, C.A. Portell, R.J. Farah, S.T. Lee, A. Pradhan, C. Morrison, A. Tadese, A.M. Juanitez, C. Lu, A. Jacob, H. Simmons, W.D. Figg, S.M. Steinberg, E.S. Jaffe, M. Roschewski, L.M. Staudt, and W.H. Wilson Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.), the Clinical Pharmacology Program (C.J.P., O.A., W.D.F.), the Molecular Imaging Branch (E.M., L.L., E.B.), and the Biostatistics and Data Management Section (S.M.S.), Center for Cancer Research, the Laboratory of Pathology, Clinical Center (S.P., T.D.-H., S.D.P., E.S.J.), and the Biometric Research Program, Division of Cancer Treatment and Diagnosis (G.W.), National Cancer Institute, the Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences (C.J.T., M.C., F.A.T.), and the Clinical Center Pharmacy Department (C.L.), National Institutes of Health, Bethesda, and Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore (S.T.L.) — all in Maryland; the Division of Hematology and Oncology, University of Virginia, Charlottesville (C.A.P.); Mario Lemieux Center for Blood Cancers, University of Pittsburgh School of Medicine, Pittsburgh (R.J.F.); and Adaptive Biotechnologies, Seattle (A.J., H.S.)

Randomized Bendamustine-Rituximab(R) + Bortezomib Induction and R + Lenalidomide Maintenance for Mantle Cell Lymphoma

Smith MR, et al.
Blood
May 2024
Authors and Affiliates
Mitchell R. Smith 1, Opeyemi A. Jegede 2, Peter Martin 3, Brian G. Till 4, Samir S. Parekh 5, David T. Yang 6, Eric D. Hsi 7, Thomas Witzig 7, Sandeep Dave 8, David Scott 9, Curtis Hanson 7, Lale Kostakoglu Shields 10, Nizar Abdel-Samad 11, Carla Casulo 12, Nancy L. Bartlett 13, Paolo F. Caimi 14, Tareq Al Baghdadi 15, Kristie A. Blum 16, Mark D. Romer 17, David J. Inwards 7, Rachel E. Lerner 18, Lynne I. Wagner 19, Richard F. Little 20 , Jonathan W. Friedberg 12, John P. Leonard 3, Brad S. Kahl 13 1. Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH*, 2. Dana Farber Cancer Institute, Boston, MA; 3. Meyer Cancer Center, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, NY; 4. Fred Hutchinson Cancer Center, Seattle, WA; 5. Mount Sinai, New York, NY; 6. University of Wisconsin Carbone Cancer Center, Madison, WI; 7. Mayo Clinic, Rochester, MN; 8. Duke University Medical Center, Durham, NC; 9. BCCA-Vancouver Cancer Centre, Vancouver, BC, Canada; 10. NYU-Langhorne Cancer Center, NY, NY; 11. The Moncton Hospital, Moncton, NB, Canada; 12. University of Rochester Medical Center-James P. Wilmot Cancer Center, Rochester, NY; 13. Washington University School of Medicine St. Louis and Siteman Cancer Center, St. Louis, MO; 14. Case Comprehensive Cancer Center, Cleveland, OH; 15. St. Joseph Mercy Hospital, Ann Arbor, MI ; 16. Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH; 17. Good Samaritan Hospital - Dayton, Kettering, OH; 18. Frauenshuh Cancer Center and Park Nicollet Institute, Minneapolis, MN; 19. University of North Carolina at Chapel Hill, Chapel Hill, NC; 20. Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle celllymphoma: 2-year safety and efficacy analysis

Wang M, et al.
Blood Advances
May 2024
Authors and Affiliates
Michael Wang (The University of Texas M.D. Anderson Cancer Center, United States) Tadeusz Robak (Medical University of Lodz, Poland) Kami Maddocks (The Ohio State University, United States) Tycel Phillips (University of Michigan Comprehensive Cancer Center, United States) Stephen Smith (University of Washington/Seattle Cancer Care Alliance, United States) David Gallinson (Summit Medical Group, United States) Roser Calvo (AstraZeneca, United States) Chuan-Chuan Wun (AstraZeneca, United States) Veerendra Munugalavadla (AstraZeneca, United States) Wojciech Jurczak (Maria Sklodowska-Curie National Research Institute of Oncology, Poland)